Veliparib and Topotecan for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With BRCA Negative or Unknown BRCA Status
Cancer Treatment and Research Communications - United Kingdom
doi 10.1016/j.ctarc.2017.09.001
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2018
Authors
Publisher
Elsevier BV